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OBJECTIVES: Establish the impact that present chemo-
therapy management is having on the quality of life (qol)
of patients being treated at the Prince Charles Hospital;
Allow comparison of the effect on the patients qol be-
tween established treatment modalities; Allow compari-
son of the effects on patients qol between established and
future trial treatment protocols. We report the interim
findings of this ongoing quality of life study. METH-
ODS: All patients referred for chemotherapy manage-
ment of their non-small cell lung cancer (NSCLC) were
asked to participate. The EORTC QLQ 30 and LC 13
were used to assess patients qol when disease restaging
tests were conducted. Data was entered into an access da-
tabase that allowed comparison. Protocols used were
CIV, CV- adjuvant-neoadjuvant setting. CG and single
agent Gemcitabine 1000mg/m2 on days 1, 8, 15, in the
palliative setting. RESULTS: Patients ages ranged 39 to
73 yrs, average age 53 yr, median, 51, mode 47years. The
sample consisted of 3 females & 12 males, 6 patients are
not reported, 3 neoadjuvant had progressive disease after
two cycles and were not followed, 3 palliative patients
died after one cycle of treatment. Of the 21 patients
treated 15 (71%) had improved Quality of Life scores
paralleled other measures of assessment. Scans show re-
sponse to single agent Gemzar in the palliative setting
and response to CIV in the neoadjuvant setting. CON-
CLUSION: we demonstrated 71% of our patients had
qol improvements. Management of patients with NSCLC
should consider chemotherapy. FUTURE DIRECTION:
An outcomes study is being conducted at two campuses
in Brisbane. This study seeks to include all newly diag-
nosed lung cancer patients and follow their progress
through their disease using clinical Quality of Life and
economic criteria to determine outcome. Comparison be-
tween treatment and within treatment arms will be com-
pared.
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SYSTEMATIC ASSESSMENT OF HEALTH-
RELATED QUALITY OF LIFE INSTRUMENTS FOR 
USE IN CLINICAL TRIALS OF NON-SMALL CELL 
LUNG CANCER
Huang JC, Veenstra DL
University of Washington, Seattle, WA, USA
OBJECTIVE: To critically evaluate the quality of health-
related quality of life (HRQoL) instruments for use in
clinical trials of non-small cell lung cancer (NSCLC).
METHODS: A structured review of literature was
conducted by searching MEDLINE (1975–2000) and
PsycINFO (1977–2000) using the keywords “lung can-
cer”, “quality of life” and “questionnaire”, and manu-
ally. HRQoL instruments that had been used in or de-
signed for lung cancer were selected for review. Each
instrument was assessed for its general features, feasibil-
ity, scoring and interpretation, and psychometric proper-
ties. RESULTS: Ten instruments were selected for review:
EORTC-QLQ30, EORTC-LC13, FACT-L, LCSS, FLIC,
CARES, CARES-SF, RSCL, FLIC and MQOL. Most
questionnaire items were appropriately generated through
multiple cycles of input from patients and clinicians. The
most studied psychometric properties were internal con-
sistency and convergent/divergent validity, with most in-
struments having Cronbach’s a 0.7 and acceptable cor-
relation coefficients for convergent/divergent validity.
Responsiveness, interpretability of the scale score, and
validity testing in cross-cultural settings were either inad-
equately evaluated or missing. All instruments have a
good readability level, an administration time less than
20 minutes, a time horizon of one week or less, and are
multilingual. All questionnaires have been used in clinical
trials for non-small cell lung cancer except CARES,
CARES-SF and MQOL. CONCLUSIONS: There are sev-
eral reliable and validated HRQoL instruments that are
appropriate for use in clinical trials of NCSLC. In partic-
ular, the EORTC-QLQ30 and its lung cancer supple-
ment, the LC13, LCSS, RSCL, FACT-L, and CARES
have greater evidence of good psychometric properties.
Further research is required to evaluate the cross-cultural
performance, score interpretability and correlation with
clinical outcomes of these instruments.
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COST OF TREATMENT FOR SQUAMOUS CELL 
CARCINOMA OF THE HEAD AND NECK IN THE 
UNITED STATES
Cronin K, Lee B, Wang D
The Lewin Group, Falls Church, VA, USA
BACKGROUND: Cancer of the head and neck is the
11th most common cancer in the US, however, there are
no published, comprehensive studies examining the costs
associated with the treatment of head and neck cancer in
the United States. The objective of this research was to
design a model to estimate the cost of treatment for squa-
mous cell carcinoma of the head and neck (SCCHN).
METHODS: A decision analytic model was designed to
project the outcomes and costs associated with SCCHN.
The model was stratified by site of disease, stage of pre-
sentation, treatment, and outcome. The most common
therapeutic options for SCCHN were modeled: 1) sur-
gery, 2) radiation therapy, 3) surgery and radiation ther-
apy, 4) radiation therapy and chemotherapy, and 5) palli-
ation. Base case data were obtained from the National
Cancer Data Base, the published literature, a modified
Delphi survey of experts, and an analysis of the Medicare
Standard Analytic Files. RESULTS: Average per patient
cost of care for SCCHN in the US was estimated to be
$20,876. Higher costs resulted for patients that present
with advanced cancers. The estimated cost of treating a
patient with Stage IV lip SCC ($19,274) was four times
that of Stage 0 lip SCC ($5,062). The site with the lowest
cost of treatment was lip ($7,261) while the highest cost
was associated with hypopharyngeal SCC ($28,584). The
cost per patient for palliative care ranged from $2,052
for lip SCC (28% of total cost of care) to $7,172 for si-
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nonasal SCC (30% of total cost of care). The lifetime
cost of managing annual incident SCCHN cases was esti-
mated to approximate $976 million. CONCLUSION:
This study found that tumor stage and location are useful
predictors of increased treatment costs. The results sug-
gest that prevention and early detection are critical in re-
ducing the treatment costs of SCCHN.
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DETECTING RECURRENT PAPILLARY OR 
FOLLICULAR THYROID CANCER IN 
CLINICALPRACTICE: NEED FOR A CHANGE?
Hooft L, Hoekstra OS
University Hospital Vrije Universiteit, Amsterdam, Netherlands
OBJECTIVES: Patients with thyroid carcinoma (TC) can
present a diagnostic dilemma when elevated tumormark-
ers (thyroglobulin, Tg) suggest relapse but whole body
131-iodine scanning (131I WBS) is negative. Then, bat-
tery of imaging modalities is available. In recent years,
positron emission tomography has been proposed as an
effective and comprehensive staging procedure. To esti-
mate the effort and yield of present clinical practice, we
performed a retrospective study. METHODS: From our
Tg database we identified all TC patients, and included
those with elevated Tg levels (&#61619; 1.5 pmol/l on
thyroid hormone medication) after ablation with 131I,
between 1-5-96 and 1-1-98, and recorded the applied di-
agnostic work-up. RESULTS: Tg data were identified
from 116 patients with TC. Twenty met the inclusion cri-
teria, 18 of which (90%) had a complicated work-up. Re-
current disease was confirmed in 16. The mean number
of imaging tests required to arrive at a clinical conclusion
was 5 (range 3–9), within a mean period of 18 months.
Since 1997, PET has been performed in 15 patients with
negative or equivocal high dose 131I WBS (8 positive and
7 negative scans). Tumor sites first disclosed by PET were
found in 5 patients. CONCLUSIONS: The current diag-
nostic trajectory in the majority of the patients with ele-
vated Tg and negative 131I WBS proved to be protracted
and complicated. Even though prognosis may not neces-
sarily be adversely affected by this delay, patient anxiety
is a considerable problem. FDG-PET may solve clinical
problems in some of these patients, but the currently
available evidence does not allow for implementation of
a routine diagnostic algorithm.
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A COST-EFFECTIVENESS ANALYSIS OF 
CLOPIDOGREL VERSUS ASPIRIN AS 
PREVENTION OF ISCHEMIC EVENTS IN 
PATIENTS WITH ESTABLISHED PERIPHERAL 
ARTERY DISEASE
Decerbo MC, Baroletti SA, Isopo S, Silva M, Talati DK
Northeastern University, Boston, MA, USA
OBJECTIVES: Since becoming widely recognized for its
antithrombotic effects in the 1970s, aspirin has become
first-line antiplatelet therapy across most patient popula-
tions. However, newer data suggests that clopidogrel is
more effective than aspirin for prevention of ischemic
events in peripheral artery disease (PAD) patients. In this
analysis, a decision analytic model was constructed in or-
der to evaluate the cost-effectiveness of clopidogrel versus
aspirin as prevention of ischemic events in patients with
established PAD. METHODS: Data on the probability of
ischemic events was extracted from the PAD subgroup of
the CAPRIE trial, in which event rates for clopidogrel
and aspirin were 3.71% and 4.86%, respectively. Costs
included in this analysis were obtained from the medical
literature. RESULTS: In the base case analysis, the ex-
pected cost of treatment over a one-year time frame with
clopidogrel and aspirin was $2075 and $1088, respec-
tively. Furthermore, to effectively treat one patient, it
would cost $2155 with clopidogrel and $1144 with aspi-
rin. An incremental cost-effectiveness analysis concluded
that one additional event of vascular death, MI, or
ischemic stroke will be prevented with clopidogrel at an
additional one-year cost of $85,826. A univariate sensi-
tivity analysis demonstrated that aspirin must have ischemic
event rates greater than 13% for clopidogrel to be the
preferred option based solely on cost. Furthermore, in or-
der for clopidogrel to be considered cost-effective with an
event rate of 3.71%, aspirin must have an event rate of
11.48%, a rate 2.4 times greater than was observed in
the CAPRIE trial. CONCLUSIONS: The result of this
analysis concluded that it would cost a third-party payer
an extra $85,826 to effectively treat one additional pa-
tient over a one-year period when using clopidogrel in-
stead of aspirin. This cost can play a major role in the de-
cision of appropriate antiplatelet therapy used to treat
PAD patients in the prevention of ischemic events.
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VENOUS THROMBOEMBOLIC (VTE) 
COMPLICATIONS FOLLOWING MAJOR 
ORTHOPEDIC SURGERY: FREQUENCY AND 
ECONOMIC CONSEQUENCES IN HOSPITAL
Gabriel S1, Dinet J1, Dispot T2, Radal C2
1Sanofi-Synthelabo, Bagneux, France; 2Medcost, Paris, France
OBJECTIVES: The risk of VTE disease in patients under-
going major orthopedic surgery (MOS) has extensively
been studied in randomised clinical trials and more re-
cently in cohort studies. Our objective was to estimate
the risk of VTE disease in a much larger population and
to calculate its economic consequences in hospital.
METHODS: We conducted a retrospective study of the
risk of occurrence and associated costs of VTE compli-
cations (including deep vein thrombosis (DVT) and pul-
monary embolism (PE)) in patients undergoing MOS
(including hip replacement, hip fracture and knee re-
placement). Data were obtained from the National inpa-
tient Diagnosis Related Group (DRG) data base with ex-
